← Back to Clinical Trials
Recruiting Phase 4 NCT07308756

Impact of Perioperative Dexmedetomidine and Esketamine on Postoperative Quality of Recovery

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition General Anesthesia
Sponsor Peking University First Hospital
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 316
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2026-01-05
Completion 2027-03
Interventions
DexmedetomidineEsketamineDexmedetomidine-esketamine

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

For patients after surgery, quality of recovery has significant impacts on the prognosis, quality of life, and rational allocation of medical resources. Dexmedetomidine and esketamine have each been used during the perioperative period and improved postoperative analgesia and subjective sleep quality. This 2x2 factorial trial is designed to explore the effects of dexmedetomidine, esketamine, and their combination on the quality of recovery in patients recovering from surgery under general anesthesia.

Eligibility Criteria

Inclusion Criteria: * Aged 18 years or over; * Scheduled to undergo surgery under general anesthesia, with an expected surgical duration of at least 1 hour; * Required patient-controlled intravenous analgesia after surgery. Exclusion Criteria: * Unable to communicate preoperatively due to visual, auditory, or verbal barriers or other reasons; * Severe bradycardia (heart rate \<50 bpm), sick sinus syndrome, or grade 2 or higher atrioventricular block without pacemaker; * History of hyperthyroidism or pheochromocytoma; * History of schizophrenia, epilepsy, Parkinson's disease, myasthenia gravis, or intracranial hypertension; * Intracranial tumor or neurosurgery; * Severe liver dysfunction (Child-Pugh class C), renal failure (requiring renal replacement therapy), or American Society of Anesthesiologists class IV or higher; * Enrolled in other clinical studies.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}